Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Buys Xcyte s T-Cell Tech for $5M to Fatten Immunotherapy Play; Deal Ties Into Dynal Acquisition

NEW YORK, Dec. 15 (GenomeWeb News) - Invitrogen will acquire Xcyte Therapies' T-cell expansion technology for $5 million in cash, the companies said today.


The acquired assets will include intellectual property for the technology, known as the "Xcellerate Process," raw materials and equipment, and clinical data from six clinical trials of Xcyte's lead product, Xcellerated T Cells.


For Invitrogen, the acquisition is aimed at buttressing the firm's immunotherapy offerings, and plays into its acquisition of Dynal, which closed in April. "We firmly believe T-cell based therapy will become an important contributor in the efforts to fight disease in the future," Oystein Amellem, business area manager for Invitrogen's Dynal Bead Based Separation group, said in a statement.


Xcyte has collaborated with Dynal Biotech in the production of Xcyte Dynabeads, the bead Xcyte uses to expand and activate T cells for "potential therapeutic indications in oncology and infectious disease," Xcyte said in a statement.


"Expansion of T cells ex vivo using Dynabeads to which anti-CD3 and anti-C28 monoclonal antibodies are linked may prove useful for the treatment of cancer, infectious diseases and recently autoimmune diseases," Amellem added.

Terms of the acquisition also call for Xcyte to receive an undisclosed percentage of any sublicensing revenue Invitrogen derives from licensing Xcyte's intellectual property for therapeutic purposes. This part of the deal is subject to certain minimum revenue requirements, the firms said.

The transaction is subject to certain customary closing conditions, including the approval of Xcyte's stockholders.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.